Reference

AMET works diligently to keep the following information updated with the most current medical aesthetic news.  This information has been supplied by numerous sources. AMET is not affiliated with any such sources, and the information provided does not reflect the views of AMET.  The function of this page is to simply provide information, and AMET does not accept responsibility or liability for any views/claims/rumors/errors that appears herein.  

7/27/2010
Generic Latisse Competitor Applies for FDA Approval
An unnamed drug maker has applied for US regulatory approval to sell a generic version of Allergan Inc's eyelash-enhancing drug Latisse before its patent protection expires.
Generic Latisse Competitor Applies for FDA Approval

An unnamed drug maker has applied for US regulatory approval to sell a generic version of Allergan Inc's eyelash-enhancing drug Latisse before its patent protection expires.

Latisse, approved in late 2008, has market exclusivity until late 2011. Last year it had sales of $73.3 million. But in the United States, the FDA disclosed last week that a company filed an application in May to market a copycat version by challenging Allergan's patent protection for the drug. The FDA didn't identify the applicant of the generic drug.

An Allergan spokeswoman acknowledged the FDA filing but couldn't comment further because the Irvine, Calif, company hasn't officially been notified by the generic challenger.

[Source: The Wall Street Journal]

http://www.plasticsurgerypractice.com/eReport/2010...

back to reference main